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Breast cancer
Ductal carcinoma in situ
(DCIS)
Screening mammography
Cancer registrationAbstract Background: There is concern about detection of ductal carcinoma in situ (DCIS)
in screening mammography. DCIS accounts for a substantial proportion of screen-detected
lesions but its effect on breast cancer mortality is debated. The International Cancer Screening
Network conducted a comparative analysis to determine variation in DCIS detection.
Patients and Methods: Data were collected during 2004–2008 on number of screening exam-
inations, detected breast cancers, DCIS cases and Globocan 2008 breast cancer incidence rates
derived from national or regional cancer registers. We calculated screen-detection rates for
breast cancers and DCIS.
Results: Data were obtained from 15 screening settings in 12 countries; 7,176,050 screening
examinations; 29,605 breast cancers and 5324 DCIS cases. The ratio between highest and low-
est breast cancer incidence was 2.88 (95% conﬁdence interval (CI) 2.76–3.00); 2.97 (95% CI
2.51–3.51) for detection of breast cancer; and 3.49 (95% CI 2.70–4.51) for detection of DCIS.
Conclusions: Considerable international variation was found in DCIS detection. This varia-
tion could not be fully explained by variation in incidence nor in breast cancer detection rates.
It suggests the potential for wide discrepancies in management of DCIS resulting in overtreat-
ment of indolent DCIS or undertreatment of potentially curable disease. Comprehensive can-
cer registration is needed to monitor DCIS detection. Efforts to understand discrepancies and
standardise management may improve care.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license. 1. Introduction
In the United States (US), the rate of ductal carcinoma
in situ (DCIS) has increased ﬁvefold in the last 25 years
[1]. This dramatic increase has been attributed to the
diﬀusion of screening mammography. Among cases
detected by screening in the US between the years 2002
and 2006 close to 24% were DCIS [2]. A marked increase
in DCIS incidence rates has also been found in Europe
[3–6]. Common belief is that DCIS advances to invasive
cancer in the absence of treatment, but the time trend
in incidence of invasive breast cancer is not consistent
with this expectation for all cases of DCIS [7–9]. It is
likely that some forms of DCIS would remain indolent
throughout the lifespan of a patient, whereas other types
have a greater propensity to advance into life-threatening
invasive disease. The natural history of screen-detected
DCIS therefore remains ambiguous. To a large extent
this is related to the variety of histological subtypes
grouped under the one label DCIS. Observational data
indicate tumour size, nuclear grade, presence/absence
of comedo-type necrosis and age to be independent prog-
nostic factors for DCIS progression [10]. While detection
of DCIS is thought to contribute to screening eﬀective-
ness [11], there is considerable debate about the overdiag-
nosis of DCIS and the negative impact of screening if
non-lethal disease is identiﬁed and treated.
To determine the variation inDCIS detection in screen-
ing mammography, we undertook a survey within the
frameworkof the InternationalCancer ScreeningNetwork
(ICSN) [12]. We focused on the age group 50 to 69 years
for which screening is recommended in all ICSN countries.
2. Patients and methods
We sought data from the ICSN countries regarding
DCIS cases identiﬁed within well-deﬁned screeningsettings between 1st January 2004 and 31st December
2008. These programmes are described in some detail
at (http://appliedresearch.cancer.gov/icsn/breast/screen
ing.html). Most of the screening settings were popula-
tion-based, organised screening programmes like the
national programme in the Netherlands, while the US
data from the Breast Cancer Surveillance Consortium
(BCSC) derived from opportunistic screening in well-
deﬁned populations. Italy included ﬁve and Switzerland
four regional programmes. For simplicity we refer to all
the screening settings as programmes. One screening
mammography examination in a woman was deﬁned
as a screening test. We asked each programme to com-
plete Excel spreadsheets of aggregate data regarding
number of screening tests performed, number of
screen-detected invasive breast cancers, DCIS cases,
and lobular carcinoma in situ (LCIS) cases. Screen-
detected cases were deﬁned according to the procedures
of the individual programmes. In some programmes, the
ﬁnal diagnostic conclusion was directly linked to each
screening examination. In the BCSC, a diagnosis within
12 months of an abnormal or positive screening exami-
nation was deﬁned as a screen-detected case. We
included data for women aged 50–69 years. Data were
reported separately for initial screens, the women’s ﬁrst
known screen or the ﬁrst registered in an organised
screening programme and subsequent screens. All
detected cases were included independently of whether
it was a ﬁrst or a subsequent lesion in a given women
or whether there were bilateral lesions. We attempted
to collect data for DCIS grade and size, but these vari-
ables were unknown for large parts of the data set,
18% for grade and 37% size, and were consequently
not used in the analysis.
In total 115 Excel ﬁles were collected from 12 coun-
tries. Detection rates for invasive breast cancer and
DCIS, respectively, were calculated as the number of
Table 1





















Czech Republic 2.5 CR Nat 2002 PR 45–69 2 M No 2007–8 937,718
Denmark
Copenhagen
3.8 CR Reg 1991 PI 50–69 2 M Yes 2004–7 48,528
Denmark Fyn 3.8 CR Reg 1993 PI 50–69 2 M Yes 2004–7 97,498
Finland 3.3 CR Nat 1987 PI,MA 50–69d 2 M Yes 2004–7 862,908
Ireland 3.2 CR Regb 2000 PI 50–64 2 M Yes 2004–8 332,359
Italye 2.8 E-mort Reg 1990 PI 50–69 2 M Yes 2006–8 1,521,426
Japan 1.3 E-mort Nat 2000 PI,MA 50–69 2 M,CBE Yes 2004–8 160,333
Luxembourg 2.4 E-mort Nat 1992 PI 50–69 2 M Yes 2006–8 45,586
Netherlands 3.2 CR Nat 1989 PI 50–74f 2 M Yes 2007 874,047
Norway 2.6 CR Nat 1996 PI 50–69 2 M Yes 2004–8 963,424
Spain Barcelona 2.0 E-mort Reg 2001 PI 50–69 2 M No 2004–8 184,748
Spain Navarra 2.0 E-mort Reg 1989 PI 45–69 2 M No 2004–8 181,992
Spain Valencia 2.0 E-mort Reg 1992 PI 45–69 2 M No 2004–8 983,452
Switzerlandg 3.2 E-mort Reg 1999 PI 50–69 2 M Yes 2004–8 176,318
United States of
America (USA)
2.4 E-reg Regc 1991 PR,MA 40–74+ 1–2 M,CBE No 2004–7 1,029,401
Nat: national; Reg: regional; PR: physician referral; PI: personal invitation; MA: media advertising; M: mammography; CBE: clinical breast
examination.
a National average breast cancer incidence rate per 1000 for women aged 50–69 according to Globocan 2008 [13]. These data include invasive
cases only. Age-standardised according to the age distribution of all reported screening tests. Globocan 2008 data source speciﬁed as: CR: National
cancer register data; E-mort: Estimated from cancer mortality data; E-reg: Estimated from regional cancer register data.
b Programme became national in 2007.
c National database covering screening in selected areas.
d Targeted women aged 50–59 until 2006.
e Data from ﬁve regional programmes: Piemonte, Valle d’Aosta, Emilia Romagna, Toscana, and Lazio.
f The age group 70–74 years has been included only since 1999.
g Data from all ﬁve operating Swiss regional programmes: Geneva, Vaud, Valais and Fribourg (2004–8), and Jura-Neuchaˆtel (2005–8).
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the number of screening tests performed in this age
group. Age-standardised detection rates were calculated
using the age distribution of all screening tests across all
countries as the standard.
Characteristics of the screening programmes such as
age group targeted and screening interval were retrieved
from the ICSN website [12]. In several of our data col-
lection countries, the collection period coincided with
a gradual shift from analogue to digital mammography,
and the programmes can therefore not be classiﬁed by
type of mammography. The ICSN website furthermore
includes only limited information on each programmes;
no information is for instance provided on criteria for
mammogram classiﬁcation, referral strategy or referral
rate. National breast cancer incidence rates (invasive
cases only) in 2008 for women aged 50–54, 55–59, 60–
64 and 65–69 years were retrieved from the Globocan
website [13] and age-standardised. It should be noted
that only part of the Globocan 2008 data derive from
national cancer registers, see Table 1 for speciﬁcation.
The programme performance was evaluated by the
ratio between the age-standardised detection rate for
invasive cases at subsequent screens and the background
breast cancer incidence rate as estimated by Globocan
data. In rough terms, in a biennial screening programme
a ratio of 1.5 corresponds to a programme with 75%sensitivity for invasive cases. The international gradient
in screening detection rates was illustrated by the ratio
between the highest and the lowest age-standardised
rates. We investigated the correlation between various
performance indicators. As the size of the individual
data sets varied considerably, and as we were interested
in the variation across programmes, we used Spearman’s
rank coeﬃcients without weights for the size of each
observation point. We merged data from the pro-
grammes for the initial and the subsequent screening
tests and calculated invasive and DCIS detection rates
for women aged 50–59 and 60–69, respectively.
3. Results
Twelve countries contributed data, 10 with national
data although with diﬀerent population coverage, and
two (Denmark and Spain) with regional data (Table 1).
In total, observations were available from 15 screening
programmes. Screening started between 1987 and 2002
and involved an increasing number of screened women
in some countries during the data reporting period. In
all countries, women aged 50–69 years were targeted
by screening, the interval being 2 years except for the
US where the interval was 1–2 years, Table 1. Between
the 12 countries the age-standardised breast cancer inci-
dence for women aged 50–69 varied from 1.31 per 1000
Fig. 1. Age-standardised breast cancer incidence rate, detection rate of invasive breast cancer and detection rate of ductal carcinoma in situ (DCIS)
per 1000 women aged 50–69 years.
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risk (RR) of 2.88 (95% conﬁdence interval (CI) 2.76–
3.00), Fig. 1.
In the age group 50–69 years, 7,176,050 screening
tests, 29,605 invasive breast cancer cases, 5,324 DCIS
cases and 233 LCIS cases were reported (Table 2). DCIS
as a proportion of all detected cases averaged 16%
across all programmes, and the rate was 0.82 per 1000
examinations. The lowest proportion was in Finland
(9%, 95% CI 8–10%) and highest in the US (24%, 95%
CI 22–25%). The proportions were close to or above
20% in Denmark, Copenhagen; Ireland; Japan and the
US, while the proportions were 10% or below in the
Czech Republic; Denmark, Fyn and Finland. Rates
were less than 0.8 per 1000 examinations for Czech
Republic, Denmark Fyn, Finland, Italy, Japan, The
Netherlands, Spain Barcelona, Spain Navarra, Spain
Valencia and greater than 0.8 per 1000 examinations
for Denmark Copenhagen, Ireland, Luxembourg, Nor-
way, Switzerland and US.
The age-standardised detection rates for invasive
breast cancer cases varied from 6.65 per 1000 in Den-
mark, Copenhagen to 2.24 per 1000 in Japan, resulting
in a RR for Denmark, Copenhagen versus Japan of
2.97 (95% CI 2.51–3.51), Fig. 1.
The age-standardised detection rates for DCIS varied
from 1.55 per 1000 in Denmark, Copenhagen to 0.45 per
1000 in Finland, resulting in a RR of 3.49 (95% CI 2.70–4.51) (Fig. 1). Both the detection rate of invasive cancer
and of DCIS decreased gradually from the highest to the
lowest rates, but the sequences were not identical.
Denmark, Copenhagen; the US and Ireland had high
DCIS detection rates as compared with their invasive
detections rates, while the Czech Republic; Finland
and Denmark, Fyn had relatively low DCIS detection
rates, Fig. 2. The diﬀerences across programmes were
less dramatic when second highest and second lowest
rates were compared, but the pattern prevailed; the
ratios being 1.66; 2.13 and 2.47 for breast cancer inci-
dence, detection of invasive breast cancer and detection
of DCIS, respectively.
Thirteen out of 15 programmes provided data by ini-
tial and subsequent screens, constituting 676,324 and
4,346,708 screens, respectively. For most countries the
detection rate of invasive cancer at subsequent screens
was close to or above 1.5 times the background inci-
dence, though with Luxembourg, where the ratio was
2.04, as an outlier, and with relative low ratios of 1.21;
1.25; 1.30 and 1.31, respectively, in The Netherlands;
Spain, Barcelona; Ireland and the US (Table 2). The
average age-standardised invasive detection rate was
7.13 per 1000 at initial screens and 4.04 at subsequent
screens, giving a ratio of subsequent to initial of 0.57
(data not shown). The average DCIS proportion was
18% in initial and 17% in subsequent screens. The subse-
quent screens on average constituted 87% of the
Table 2
































Czech Republic 699,726 3276 359 31 3666 4.68 4.63 0.51 0.51 10 – –
Denmark
Copenhagen
47,249 317 73 0 390 6.71 6.65 1.55 1.55 19 1.38 1.71
Denmark Fyn 97,176 577 63 0 640 5.94 5.83 0.65 0.64 10 0.62 1.55
Finland 862,908 3810 361 17 4188 4.42 4.81 0.42 0.45 9 0.44 1.46
Ireland 331,854 1626 393 1 2020 4.90 5.06 1.18 1.21 19 1.01 1.30
Italy 1,453,292 6051 1066 97 7214 4.16 3.98 0.73 0.72 15 – –
Japan 106,898 241 72 1 314 2.25 2.24 0.67 0.66 23 0.62 1.43
Luxembourg 45,586 241 48 4 293 5.29 5.33 1.05 1.06 16 1.06 2.04
Netherlands 718,202 2939 576 1 3516 4.09 4.06 0.80 0.80 16 0.76 1.21
Norway 963,424 4147 899 34 5080 4.30 4.27 0.93 0.93 18 0.86 1.60
Spain
Barcelona
184,748 508 90 2 600 2.75 2.74 0.49 0.49 15 0.41 1.25
Spain Navarra 131,948 435 95 4 534 3.30 3.27 0.72 0.71 18 0.68 1.61
Spain Valencia 739,829 2607 422 15 3044 3.52 3.49 0.57 0.57 14 0.55 1.71




616,892 1959 617 19 2595 3.18 3.19 1.00 1.00 24 0.98 1.31
Total 7,176,050 29,605 5324 233 35,162 4.30c 4.29c 0.82c 0.82c 16c 0.78d 1.50d
DCIS: Ductal carcinoma in situ, including carcinoma in situ unspeciﬁed; LCIS: Lobular carcinoma in situ.
a Age standardised, using the age distribution of all screening tests as standard.
b Subsequent screens only.
c Average for the 15 programmes.
d Average for the 13 programmes.
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rates for DCIS were consequently in most programmes
close to those for all screens (Table 2). The average
age-standardised DCIS detection rate was 1.30 per
1000 at initial screens and 0.78 at subsequent screens,
giving a ratio of subsequent to initial of 0.60 (data not
shown).
Although the overall DCIS detection rate increased
from 0.68 to 0.83 per 1000 from age 50–59 to age 60–
69, the DCIS proportion of all detected lesions
decreased from 16.6% to 13.9% (Table 3). Among
women aged 50–59, the DCIS detection rate per 1000
dropped from 1.01 to 0.64 from initial to subsequent
screens, resulting in a ratio of subsequent to initial of
0.63. For invasive breast cancer the equivalent ratio
was 0.75; 0.63 versus 0.75 (p = 0.002), which may
indicate a longer lead time for DCIS than for invasive
cancer. Among women aged 60–69, both ratios were
0.57. The age-standardised DCIS detection rate was on
average 0.66 per 1000 in the ﬁve programmes without
double reading versus 0.91 per 1000 in the remaining
programmes with double reading, however, with large
variation in both groups. A 2 year screening interval
was recommended in all programmes except in the Uni-
ted States of America (USA), and it was therefore not
possible to investigate DCIS detection as a function of
screening interval.4. Discussion
We studied DCIS and invasive breast cancer detec-
tion through screening mammography in 15 screening
programmes in Europe, the US and Japan. The back-
ground incidence rate of breast cancer varied threefold
across these settings. An approximately threefold varia-
tion was also found for the screening detection rates of
invasive breast cancer. For most screening programmes
the detection rates of invasive disease at subsequent
screens divided by the incidence was close to or above
1.5. The ratio of 2.04 for Luxembourg could point to
over diagnosis, and the ratios of 1.21; 1.25; and 1.30
for The Netherlands; Spain, Barcelona and Ireland,
respectively, could point to a somewhat lower sensitiv-
ity. Given the cross-sectional nature of the data and
the fact that concurrent rather than background inci-
dence expected in the absence of screening has been
used, these ratios should be interpreted with caution.
The somewhat lower ratio of 1.31 for the US can be
explained by the shorter screening interval, compared
to European countries, and therefore lower expected
incidence.
When it came to DCIS detection there were large dif-
ferences across programmes with an approximately 3.5-
fold variation. The DCIS detection rates were consider-
ably higher than expected based in the detection rates
Fig. 2. Detection rate of invasive breast cancer versus detection rate of ductal carcinoma in situ (DCIS) both per 1000 women aged 50–69 years.
Table 3
Crude detection rates of invasive breast cancer and ductal carcinoma in situ (DCIS) by initial versus subsequent screening test.
Age Screening test Invasive DCIS DCIS % of detected lesions (%) Invasive per 1000 DCIS per 1000
50–59 All 14,679 2914 16.6 3.43 0.68
Initial (I)a 2543 584 18.7 4.39 1.01
Subseq (S)a 8426 1643 16.3 3.29 0.64
Ratio S/I S/I 0.75 S/I 0.63
60–69 All 14,926 2410 13.9 5.13 0.83
Initial (I)a 805 146 15.4 8.27 1.50
Subseq (S)a 8504 1526 15.2 4.75 0.85
Ratio S/I S/I 0.57 S/I 0.57
a Data not available from the Czech Republic and Italy.
190 E. Lynge et al. / European Journal of Cancer 50 (2014) 185–192for invasive cancer in Denmark, Copenhagen; Ireland,
Luxembourg, Switzerland, and the US, while the Czech
Republic; Finland; Spain Valencia, and Denmark, Fyn
had low detection rates. No other country exceeded
the US 24% detection rate for DCIS in screened cases.
The variation across programmes in DCIS detection
rates may in part be due to technology. In Copenhagen,
Denmark the detection rate increased when high resolu-
tion ultrasound and stereotactic breast biopsies were
introduced in the early 2000s for the diagnostic assess-
ment of women with Breast Imaging Reporting and
Data System (BI-RADS) 0 screening mammograms
[14]. In some [15] but not all [16] settings, DCIS detec-
tion has furthermore been found to increase with the
introduction of digital mammography. The variation
may also be due to variability in diagnostic criteriaamong pathologists both within and between countries.
In a quality assessment scheme for breast pathology in
the United Kingdom (UK), the overall kappa value
for diagnosis of in situ/microinvasive cases was 0.76
[17], so variation does occur even within a country. Var-
iation across countries can also be expected based on
diﬀerent criteria and norms for diagnosis since at least
three systems of classiﬁcation are in use throughout
the world [18]. Comprehensive and standardised regis-
tration of all DCIS cases is an important task for
national as well as regional cancer registries.
The point of this paper, however, is that variation in
DCIS detection is extensive. Our data indicate that this
variation cannot be explained by diﬀerences in breast
cancer incidence in these populations. The amount of
DCIS detection is therefore expected to have implica-
E. Lynge et al. / European Journal of Cancer 50 (2014) 185–192 191tions for the unintended morbidity of screening. Women
diagnosed with DCIS have a long-term, disease-free sur-
vival of 96–98% when treated with current therapies [19]
so the morbidity of treatment is very important. In the
US approximately 30% of women with DCIS are treated
with mastectomy, 30% with conservative surgery alone,
and 40% with conservative surgery and radiotherapy [1].
Now that the present study has demonstrated the world-
wide variation in DCIS detection, we need in-depth
studies on possible determinants of DCIS detection,
and we need information about variation in DCIS treat-
ment around the world.
Treatment decisions are made based on the extent
and aggressiveness of the disease. Eﬀorts are underway
to develop biological markers to distinguish between
progressive and non-progressive DCIS lesions [20,21],
but it may still take some time before such markers
are available for clinical use. Future biomarkers for
DCIS could help to distinguish between low-risk lesions
that could be observed versus high-risk lesions requiring
treatment. For small invasive cancers, mammographic
pattern has been shown to correlate with prognosis
[22], and such studies may also be valuable for classiﬁca-
tion of DCIS. Further studies into combined mammo-
graphic appearance and histopathology might be
promising for diﬀerentiation between clinically signiﬁ-
cant and indolent DCIS.
We studied cross-sectional data reported in a stand-
ardised format from 15 screening programmes. The data
collection was standardised. The coordinating centre in
Torino, Italy sent the same excel spread sheet to all data
providers, and checked for logical inconsistencies and
numbers across the tables. Data providers were asked
to correct eventual irregularities, and the data were re-
checked prior to analysis. The data sets varied consider-
ably in size from the more than 1.4 million screening
tests reported from Italy to the 45,000 screening tests
reported from Luxembourg. The nationally aggregated
data sets, such as the BCSC data from seven US screen-
ing programmes [2], are expected to represent the aver-
age across programmes. It is not surprising on this
basis that the small Danish screening programmes fell
at the extremes of DCIS detection, whereas the US data
came closer to the average.
The low proportion of DCIS cases in Finland is note-
worthy as the Finnish screening programme has repeat-
edly been shown to have reduced breast cancer mortality
in Finnish women. This was true both in the early phase
where an approximately 34% reduction in breast cancer
mortality was found [23], and in a later phase where a
28% reduction was found [24]. A low DCIS detection
rate has thus been shown to be no hindrance for a
screening programme to achieve its aim of reducing
breast cancer mortality.
In conclusion, this ﬁrst international comparison of
DCIS detection rates in screening mammographyprogrammes reveals considerable variation, indicating
an opportunity for standardisation. The low DCIS
detection rate in Finland in the presence of a mortality
reduction suggests there is room to reduce the DCIS
detection rates in other programmes, and therefore
reduce the morbidity associated with screening. The dif-
ferences in DCIS rates also oﬀers an opportunity for
international collaboration on recommendations for
DCIS detection and diagnosis in screening mammogra-
phy to reduce the wide variation in potential morbidity
from overtreatment, while optimising outcomes by
avoiding undertreatment of early, high-risk disease.Conﬂict of interest statement
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